Body Composition changes with Testosterone Replacement Therapy

[liftsiron]

J Spinal Cord Med. 2017 Aug 3:1-21. doi: 10.1080/10790268.2017.1357917. [Epub ahead of print]

Body Composition changes with Testosterone Replacement Therapy following Spinal Cord Injury and Aging. A Mini Review.
Nightingale TE1,2, Moore P1, Harman J1, Khalil R1, Gill RS3,4, Castillo T1,2, Adler RA3,4, Gorgey AS1,2.
Author information
Abstract

Context Hypogonadism is a male clinical condition in which the body does not produce enough testosterone. Testosterone plays a key role in maintaining body composition, bone mineral density, sexual function, mood, erythropoiesis, cognition and quality of life. Hypogonadism can occur due to several underlying pathologies during aging and in men with physical disabilities, such as spinal cord injury (SCI). This condition is often under diagnosed and as a result, symptoms undertreated. Methods In this mini-review, we propose that testosterone replacement therapy (TRT) may be a viable strategy to improve lean body mass (LBM) and fat mass (FM) in men with SCI. Evidence Synthesis Supplementing the limited data from SCI cohorts with consistent findings from studies in non-disabled aging men, we present evidence that, relative to placebo, transdermal TRT can increase LBM and reduce FM over 3-36 months. The impact of TRT on bone mineral density and metabolism is also discussed, with particular relevance for persons with SCI. Moreover, the risks of TRT remain controversial and pertinent safety considerations related to transdermal administration are outlined. Conclusion Further research is necessary to help develop clinical guidelines for the specific dose and duration of TRT in persons with SCI. Therefore, we call for more high-quality randomized controlled trials to examine the efficacy and safety of TRT in this population, which experiences an increased risk of cardiometabolic diseases as a result of deleterious body composition changes after injury.
KEYWORDS:

Body composition; Fat mass; Lean body mass; Spinal cord injury; Testosterone replacement therapy

[water43]

I find this interesting being that trt helps me be more able to be more active better control...and to have better motor skills of course I tell my doc I function better on a higher than reference like 1200ng/dl now I think ive heard that just test alone will suck minerals from bones if a person added a lo dose nandroline it nullifies the mineral density thing I think not sure at all........and yes I,m disabled spinal chord and brain injuries
.

[liftsiron]

From studies I read low test equals loss of bone density.

Long Term Testosterone Treatment in Elderly
Abstract | Introduction: Late-onset hypogonadism (LOH) is diagnosed when declining testosterone concentrations in the aging male cause unwanted symptoms such as erectile dysfunction (ED), reduced bone density and muscle strength, and increased visceral obesity. Testosterone deficiency is also associated with insulin resistance and the metabolic syndrome (MetS). Restoring testosterone to physiological concentrations has beneficial effects on many of these symptoms; however, it is not known whether these effects can be sustained in the long term.

Aims: To investigate whether treatment with testosterone undecanoate (TU) has a long-term and sustained effect on parameters affected by the MetS in men with LOH and ED, to determine whether long-term testosterone treatment can improve the overall health-related quality of life in these men, and to establish the safety of long-term testosterone treatment.

Methods: Two hundred sixty-one patients (mean age 59.5?±?8.4 years) diagnosed with LOH and ED were treated with long-acting TU in a prospective, observational, and longitudinal registry study. Men received intramuscular injections of 1,000?mg TU at day 1, at week 6, and every 3 months thereafter.

Main Outcome Measures: Parameters affected by the MetS, including obesity parameters (body weight, waist circumference, and body mass index [BMI]), total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, glucose, HbA1c (glycated hemoglobin), and blood pressure, as well as total testosterone levels and health-related quality of life, were assessed.

Results: We found TU significantly improved obesity parameters (body weight, waist circumference, and BMI) and lowered total cholesterol, LDL cholesterol, triglycerides, fasting blood glucose, HbA1c, and blood pressure over the 5-year study. HDL cholesterol was increased. TU treatment resulted in a sustained improvement in erectile function and muscle and joint pain, which contributed to an improvement in long-term health-related quality of life. Furthermore, we found a relationship between health-related quality of life and waist circumference. Finally, we found no evidence that long-term treatment with TU increases the risk of prostate carcinoma.

Conclusion: Long-term TU in men with LOH and ED reduces obesity parameters and improves metabolic syndrome and health-related quality of life. Yassin DJ, Doros G, Hammerer PG, and Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–1576.

The Journal of Sexual Medicine
Volume 11, Issue 6, pages 1567–1576, June 2014

Dany-Jan Yassin MBBS1,*, Gheorghe Doros PhD2, Peter G. Hammerer MD, PhD1 andAksam A. Yassin MD, PhD, EdD3,4
Article first published online: 8 APR 2014

DOI: 10.1111/jsm.12523

© 2014 International Society for Sexual Medicine

[liftsiron]

Deca is very good to help with bone density.



Nandrolone Decanoate Increases Bone Mineral Density in Elderly Patients with Osteopor

By Anne Jacobson


WASHINGTON, DC -- May 15, 2002 -- Treatment with nandrolone decanoate increases bone mineral density, increases lean body mass, and reduces the risk of vertebral fracture in elderly women with osteoporosis, according to a new study.

"In addition to increasing bone mineral density, this treatment had a dramatic impact on the well-being of our patients," Alberto Frisoli Jr., MD, of the Universidade Federal De Sao Paulo, Brazil, said in an interview with Doctor's Guide.

Dr. Frisoli presented the findings Saturday at the annual scientific meeting of the American Geriatrics Society in Washington, DC.

To evaluate the effect of nandrolone decanoate on bone mineral density, Dr. Frisoli and colleagues conducted a double-blind, randomised clinical trial of 65 osteoporotic women aged 70 years or older.

The researchers randomly assigned the women to injections of nandrolone decanoate 50 mg (32 women) or placebo (33 women) every three weeks for two years. The women also took 500 mg calcium tablets daily.

At the beginning of the study and at 12 and 24 months after treatment, bone mineral density was measured by dual energy X-ray absorptiometry exam.

Dr. Frisoli found that compared with those in the placebo group, patients treated for two years with nandrolone decanoate had a significantly greater increase in bone mineral density according to measurements taken at the femoral neck (p=0.01) and trochanter (p=0.02).

Women treated with nandrolone decanoate experienced significant increases above baseline in bone mineral density at the lumbar spine (3.4 percent and 3.7 percent in the first and second years, respectively; p<0.05) and femoral neck (4.1 percent and 4.7 percent; p<0.05).

In addition, lean body mass among the nandrolone decanoate group showed significant increase above baseline -- 6.2 percent in the first year and 11.9 percent in the second year of treatment. This increase was significantly greater in women treated with nandrolone decanoate than in placebo-treated women (p<0.002).

New vertebral fractures were significantly lower in the nandrolone decanoate group than in the placebo group (21 percent vs. 43 percent; p<0.05).

"It is important, even late in life, to see these kinds of health benefits," Dr. Frisoli concluded.